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Abstract
Background: In Norway, women with low-grade squamous intraepithelial lesions (LSIL) are followed up after six months in
order to decide whether they should undergo further follow-up or be referred back to the screening interval of three years.
A high specificity and positive predictive value (PPV) of the triage test is important to avoid unnecessary diagnostic and
therapeutic procedures.
Materials and Methods: At the University Hospital of North Norway, repeat cytology and the HPV mRNA test PreTect HPV-
Proofer, detecting E6/E7 mRNA from HPV types 16, 18, 31, 33 and 45, are used in triage of women with ASC-US and LSIL. In
this study, women with LSIL cytology in the period 2005–2008 were included (n = 522). Two triage methods were evaluated
in two separate groups: repeat cytology only (n = 225) and HPV mRNA testing in addition to repeat cytology (n = 297).
Histologically confirmed cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) was used as the study endpoint.
Results: Of 522 women with LSIL, 207 had biopsies and 125 of them had CIN2+. The sensitivity and specificity of repeat
cytology (ASC-US or worse) were 85.7% (95% confidence interval (CI): 72.1, 92.2) and 54.4 % (95% CI: 46.9, 61.9), respectively.
The sensitivity and specificity of the HPV mRNA test were 94.2% (95% CI: 88.7, 99.7) and 86.0% (95% CI: 81.5, 90.5),
respectively. The PPV of repeat cytology was 38.4% (95% CI: 29.9, 46.9) compared to 67.0% (95% CI: 57.7, 76.4) of the HPV
mRNA test.
Conclusion: HPV mRNA testing was more sensitive and specific than repeat cytology in triage of women with LSIL cytology.
In addition, the HPV mRNA test showed higher PPV. These data indicate that the HPV mRNA test is a better triage test for
women with LSIL than repeat cytology.
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Introduction
Infection Human Papillomavirus (HPV) is a necessary cause of
cervical cancer. In Norway, the cervical cancer screening program
is based on cytology. The rationale of cervical cancer cytological
screening is to identify and treat high-grade cervical intraepithelial
neoplasia (CIN) (precancerous lesions) in order to prevent its
progression to invasive cancer. Women with high-grade intraep-
ithelial squamous lesions (HSIL) detected at cytological screening
are referred to further assessment with colposcopy and biop-
sy[1,2]. Women with minor cervical lesions have a small but
significantly increased risk of developing cervical cancer compared
to women with normal smears. The purpose of triage is to identify
women needing further follow-up by colposcopy and biopsy to
detect high grade cervical dysplasia or cancer (CIN2+). In case of
atypical squamous cell of undetermined significance (ASC-US), it
is now widely recognized that triage with an HPV DNA test is
more sensitive, but less specific than repeat cytology[3,4]. For low-
grade squamous intraepithelial lesions (LSIL) however, recom-
mendations regarding the best triage method are conflicting and
vary from repeat cytology, HPV testing or direct referral to
colposcopy[5,6]. Meta-analyses indicate that triage of LSIL with a
high-risk HPV DNA test is not more sensitive and substantially less
specific than repeat cytology[3,4]. In some studies, HPV-based
triage of LSIL in women older than 30–35 years has been
suggested[7,8], but other studies have not confirmed this[9,10].
Defining the best strategy to triage LSIL lesions is therefore
identified as a priority for research.
In Norway, HPV testing has been included in triage since 2005.
If the cytological findings are defined as ASC-US or LSIL, women
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are referred to repeat cytology and HPV test after 6 months. If the
repeat cytology reveals ASC-US or LSIL and the HPV test is
positive, the patient is referred to colposcopy and biopsy. Women
with normal Pap-smear at repeat cytology, but with a positive
HPV result, are tested for HPV persistence and if positive, referred
to colposcopy. Women with cytological findings defined as high
grade squamous intraepithelial lesion (HSIL) or atypical squamous
cell cannot exclude HSIL (ASC-H) at triage are referred to
colposcopy and biopsy independent of the HPV result. The flow-
chart showing the guidelines for follow-up of minor cytological
lesions is presented in Sørbye et al., 2010b[11].
In the routine diagnostic practice at the University Hospital of
North Norway (UNN), the HPV E6/E7 mRNA test PreTect
HPV-Proofer is used in the triage of women with ASC-US or
LSIL. In the current study, the accuracy of two triage methods to
predict underlying or incipient CIN2+ was assessed, in women
with a first result of LSIL. The first group was triaged with
repeat cytology only whereas the second group was triaged with




The Regional Committee for Research Ethics (REK Sør-Øst C)
has approved the study. Written consent from the patients for their
information to be stored in the hospital database and used for
research was not needed because the data were obtained and
analyzed anonymously.
In the routine diagnostic practice at the University Hospital of
North Norway, the HPV E6/E7 mRNA test PreTect HPV-
Proofer (detecting E6/E7 mRNA from the HPV types 16, 18, 31,
33 and 45; NorChip AS, Norway) is used in the triage of women
with a Pap-smear showing ASC-US or LSIL. The Department of
Clinical Pathology receives cervical smears from the population of
Troms and Finnmark County. Approximately 23 000 cervical
smears are analysed each year. In 2005–2008, smears from 57 560
women aged 25–69 years were processed. During that period, 849
women (1.5%) had a cytological result of LSIL.
Some patients were excluded from the study population. First of
all, women with previous treatment of CIN2+ were excluded
(n = 41). Also, women with a previous abnormal smear were
excluded (n = 209), since they are managed differently and because
they are at higher risk of having a high-grade lesion compared to
women with a first LSIL result. According to the national
guidelines, women with LSIL should be followed up with two
normal Pap-smears at least 12 months apart or alternatively, with
one normal liquid based cytology (LBC) and a negative HPV-test,
before returning to routine screening at an interval of three
years[11]. Due to this, women with only one normal Pap-smear
during follow-up (n = 23) were excluded from the study. Lastly,
women with one or several abnormal Pap-smears and/or a
positive HPV-test at follow-up but without biopsy were excluded
(n = 54).
Considering the criteria above, 522 of 849 (61.5%) women with
LSIL were included in the study. Among these 522 women, an
LBC follow-up sample was taken for 297 women (56.9%), allowing
for additional HPV mRNA testing. From the other 225 women
Figure 1. Flow chart showing the two study populations.
doi:10.1371/journal.pone.0024083.g001
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(43.1%), a conventional Pap-smear was received not allowing for
HPV analysis (see Figure 1 and Table 1).
In LBC, cells were extracted from the ThinPrepH 2000 (Cytyc
Corporation, Marlborough, MA, USA) for cytological examina-
tion. Of the remnant liquid with cervical cells, DNA/RNA was
isolated from 5 ml sample and eluted in 50 ml elution buffer and
analysed with PreTect HPV-Proofer. The mRNA testing was
performed according to the manufacturer’s instructions (NorChip
AS) and in accordance with national guidelines for HPV
testing[11].
Cytological and histological diagnoses were obtained from the
diagnostic database (SymPathy) at the Department of Clinical
Pathology, UNN. Biopsies were evaluated by experienced pathol-
ogists and histological results were reported using CIN terminolo-
gy[12]. In Norway, the threshold for treatment by conisation is
CIN2. Women with benign or CIN1 histology are advised to be
followed up with a new Pap-smear and HPV testing after 6–12
months. Biopsies with uncertain cellular changes are analyzed with
p16(INK4a) immunostaining (CINtecH Histology, MTM, Heidel-
berg, Germany) in order to detect occult CIN lesions.
Outcome assessment was based on the histological result of
biopsies, where CIN2+ was considered as the target disease and
CIN1 and CIN0 (no CIN) were considered as absence of disease.
Moreover, women with a complete negative follow-up (two
consecutive negative Pap-smears or double negative LBC/mRNA
HPV result) were assumed to be free of disease. The clinical
sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated in 262 tables for cytology
(with cut-off ASC-US+ and ASC-H+, respectively), for the HPV-
test alone, and HPV-test in combinations with cytology (with cut-
off ASC-US+ and ASC-H+). Pearson’s Chi square was used to
assesses differences in the accuracy of repeat cytology alone, HPV-
testing alone and HPV-testing in combination with cytology.
The statistical computations were performed with the software
R version 2.9.0 (2009-04-17), http://www.r-project.org/. P-value
,0.05 was considered statistically significant.
Results
In Table 1, outcomes by triage cytology 6 months after the
index LSIL diagnosis are presented for all the 522 women
included. Furthermore, the PPVs for the different cytological
triage results are presented.
Of the 225 women in the ‘‘repeat cytology only’’ group (Tables 2
and 3), 85 women were referred to biopsy; 56 women (24.9%) had
CIN2+; 29 women had CIN1 or CIN0. Hundred and forty women
were not referred to histology due to two normal Pap-smears 6
months apart or alternatively one normal LBC and a negative HPV
result which was considered as equivalent to ‘‘no disease’’.
Altogether, 169 women showed a negative outcome (29 with a
negative biopsy and 140 with negative follow-up with cytology and
HPV testing). The accuracy for CIN2+ of triage with cytology with
cut-off ASC-US+ is presented in Table 2. The estimates of sensitivity,
specificity, PPV and NPV were 85.7%, 54.4%, 38.4% and 92.0%,
respectively. With cut-off ASC-H+, the sensitivity was 33.9 %, the
specificity 97.6%, the PPV 82.6% and the NPV 81.7% (Table 3).
Of the 297 women with HPV mRNA test (Tables 4
Table 5Table 6), 122 women were referred to biopsy; 69 women
(23.2%) had CIN2+; 53 women had CIN1 or CIN0. Altogether,
228 had a negative outcome (53 with a negative biopsy and 175











Normal 221 35 12 5.4 2.4, 8.4
ASC-US 90 29 15 16.7 9.0, 24.4
LSIL 154 87 54 35.1 27.5, 42.6
ASC-H 30 29 21 70.0 53.6, 86.4
HSIL 27 27 23 85.2 71.8, 98.6
Total 522 207 125 23.9 20.3, 27.6
1)LSIL = low-grade squamous intraepithelial lesions.
2)CIN2+ = CIN2, CIN3 and cancer.
doi:10.1371/journal.pone.0024083.t001
Table 2. Outcome for the 225 women triaged only with repeat cytology when cut-off is ASC-US+ 1).
Cytological findings Outcome % 95% CI
CIN2+ 3) ,CIN2 4) Total 5) Sensitivity 85.7 72.1, 92.2
ASC-US+ 48 77 125 Specificity 54.4 46.9, 61.9
NILM 2) 8 92 100 PPV 38.4 29.9, 46.9
Total 56 169 225 NPV 92.0 86.7, 97.3
1)ASC-US = atypical squamous cell of undetermined significance, ASC-US+ = ASC-US, LSIL, ASC-H and HSIL.
2)NILM = Negative for intraepithelial lesion or malignancy.
3)Prevalence CIN2+ 24.9% (95% CI, 19.2, 30.5).
4),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 (n = 29) and women referred back to screening because of two normal follow-up smears 12
months apart (n = 140).
5)Chi square = 25.9, p,0.001.
doi:10.1371/journal.pone.0024083.t002
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with negative follow-up with cytology and HPV testing). The
accuracy parameters for triage with HPV mRNA only are shown
in Table 4. The estimates of sensitivity, specificity, PPV and NPV
were 94.2%, 86.0%, 67.0%, and 98.0%, respectively. HPV
mRNA test in combination with cytology with cut-off ASC-US+
has a specificity of 47.4% and a PPV of 36.5% (Table 5).
Sensitivity and NPV were not evaluated for the combination since
by design they must be 100%. The HPV mRNA test in
combination with cytology with cut-off ASC-H+ had sensitivity
98.6%, specificity 83.8% and PPV 64.8% (Table 6).
In total, 7 of the 522 women (1.3%) with LSIL were diagnosed
with cervical cancer in the follow-up. Two were detected in the
‘‘repeat cytology only’’ group and five were detected in the HPV
group. The five women with cervical cancer in the HPV group
were all HPV mRNA positive for HPV type 16 (data not shown).
Discussion
The main cause of invasive cervical cancer is the deregulated
and persistent production of HPV E6 and E7 oncoproteins[13].
Hence, HPV E6/E7 mRNA is a rational target for detecting HPV
infections leading to cellular transformation. PreTect HPV-
Proofer detects E6/E7 mRNA of the five main high-risk HPV
types 16, 18, 31, 33, and 45. Due to the higher clinical specificity
and PPV of this method compared to other HPV tests[14–18], this
was the method of choice at our hospital when HPV testing was
introduced in triage of women with minor cytological lesions in
Norway.
When summarizing results from all women included in the
study (Table 1), 125 of 522 women (23.9%) had CIN2+ confirmed
by biopsy. Further, the PPV of ASC-US and LSIL in repeat
cytology after an LSIL diagnosis was relatively low, i.e., the chance
of having disease even with a 6 months persistent low-grade
diagnosis was concordantly relatively low. Previously, before HPV
testing was included in clinical practice, all women with persistent
ASC-US/LSIL were referred to follow-up after one year. In
current practice, this is still the case for women with repeated
ASC-US/LSIL and a negative HPV mRNA result. Women with a
positive HPV result however, are referred directly to colposcopy
and biopsy[11]. A high PPV of the HPV test is therefore important
in order to avoid unnecessary follow-up, both with regard to
follow-up costs to the health care system and with regard to
unnecessary psychological stress among patients. In addition, it is
known that HPV tests identify lesions not found by cytology and
thereby contribute in increasing the overall clinical sensitivity of
the screening program[3,4,19–23].
It is also important to have in mind that in clinical practice, the
cytological diagnosis is commonly influenced by the HPV result.
We see a tendency that a preliminary diagnosis of for example
normal or ASC-US is upgraded when a positive HPV mRNA
result is acknowledged. As a result, the clinical sensitivity of
cytology as such will be over-estimated. In order to get two groups
for comparison, a study with two separate arms was conducted.
One arm with repeat cytology only and one arm with both repeat
cytology and HPV test. National guidelines recommend that a
woman with LSIL should be followed up with repeat cytology and
an HPV test. The HPV-test however is not always performed due
to use of traditional Pap-smears instead of LBC, a method not
allowing for HPV testing. This made it possible to get a separate
arm with repeat cytology only. The HPV test result is objective
and is not dependent on the cytological diagnosis. Women referred
to histology based on the cytological result alone (i.e., having a
negative HPV result) made it possible to calculate clinical
properties also including HPV negative results.
Table 3. Outcome for the 225 women triaged only with repeat cytology when the cut-off is ASC-H+.
Cytological findings Outcome % 95% CI
CIN2+ ,CIN2 2) Total 3) Sensitivity 33.9 21.5, 46.3
ASC-H+1) 19 4 23 Specificity 97.6 95.3, 99.9
,ASC-H 37 165 202 PPV 82.6 67.1, 98.1
Total 56 169 225 NPV 81.7 76.4, 87.0
1)ASC-H = atypical squamous cell cannot exclude HSIL, ASC-H+ = ASC-H and HSIL.
2),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 (n = 29) and women referred back to screening because of two normal follow-up smears 12
months apart (n = 140).
3)Chi square = 42.3, p,0.001.
doi:10.1371/journal.pone.0024083.t003
Table 4. Outcome for the 297 women triaged only with HPV mRNA.
HPV mRNA result Outcome % % 95% CI
CIN2+ 1) ,CIN2 2) Total 3) Sensitivity 94.2 88.7, 99.7
Positive 65 32 97 Specificity 86.0 81.5, 90.5
Negative 4 196 200 PPV 67.0 57.7, 76.4
Total 69 228 297 NPV 98.0 96.1, 99.9
Number of women found with high grade lesion (CIN2+) and number of women referred back to the screening program (,CIN2).
1)Prevalence CIN2+ 23.2% (95% CI, 18.4, 28.0).
2),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 (n = 53) and women referred back to screening because of two normal follow-up smears 12
months apart or one normal LBC and a negative HPV result (n = 175).
3)Chi square = 151.2, p,0.001.
doi:10.1371/journal.pone.0024083.t004
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Until 2006, only conventional Pap-smears were used. When
HPV-testing was introduced, liquid based cytology was recom-
mended, but still almost half of the samples for repeat cytology are
conventional Pap-smears. This can partly be explained by the fact
that doctors are not properly informed about the possibility to
perform concomitant HPV-test using LBC. Thus, the physician,
and not the patient, is the reason for HPV-testing not being
performed. Based on the above, one limitation of the study is the
absence of formal randomization, which can result in imbalanced
groups. Still, one argument about comparability is the similar age
and similar prevalences of CIN2+. The age was similar of the two
groups with overlapping confidence intervals. In the group with
repeat cytology only the average age was 36.7 years (95 % CI:
35.6, 37.8); the median age was 34 years. In the HPV group the
average age was 37.8 years (95 % CI: 36.5, 39.1); the median age
was 36 years. The prevalence of CIN2+ was similar in the two
groups (24.9% and 23.2%, respectively).
Another limitation of the study is a relatively young study
population due to the exclusion of women with previous abnormal
smears or HPV tests and the population will therefore not reflect a
general LSIL population.
Referral to biopsy in the HPV-category is based on both the
cytology and the HPV result and therefore does not represent the
true number of women referred to biopsy based on HPV testing
alone. For example, women with HSIL and ASC-H are always
referred to biopsy independent of the HPV result. An argument
against differential intensity of verification in the repeat cytology
only group and the HPV group is the similar biopsy referral rate.
The referral rate for biopsy was similar in the two groups (37.8%
and 41.1%, respectively).
With regard to repeat cytology, statistical parameters were
calculated both at cutoff ASC-US+ and ASC-H+. The reason for
this is different follow up in the two groups. Women with ASC-H+
are referred to further assessment with colposcopy and biopsy.
Women with ASC-US and LSIL are followed up with cytology
and HPV-test. Repeat cytology with cut-off ASC-US+ has a high
sensitivity (85.7%) for CIN2+, but only a moderate specificity
(54.4%). In contrast, repeat cytology with cut-off ASC-H+ has a
low sensitivity (33.9%), but a high specificity (97.6%). The
combination of HPV mRNA testing and cytology with cut-off
ASC-H+ has both high sensitivity (98.6%) and high specificity
(83.8%). For comparison, the average specificity of the Hybrid
Capture 2 HPV DNA test in triage of LSIL is 28.6% (95% CI:
22.2, 35.0)[24] and generally, high HPV positivity among women
with LSIL explains why HPV DNA testing is not recommended in
triage of women with LSIL[9].
In the present study, the HPV mRNA test shows a specificity of
86.0 % (95% CI: 81.5, 90.5) and has previously been shown to
have a low positivity rate in woman with LSIL[25]. Also, previous
data on HPV mRNA testing in the triage of ASC-US and
LSIL[11,25] show that the HPV mRNA test, due to a high
specificity and positive predictive value (PPV), is valuable in the
triage of women with minor cytological cervical lesions as it gives
important information in terms of further follow-up. In fact, when
the HPV result is positive, the data suggest direct treatment for
women above 40 years of age or for women with a concurrent
cytological HSIL diagnosis, contributing to better clinical safety for
these women[11].
In the present study, the HPV mRNA test is more sensitive and
significantly more specific than repeat cytology in triage of women
with LSIL cytology. In addition, the HPV mRNA test has a
significantly higher PPV and NPV than cytology alone. A high Chi
square indicates high accuracy for the triage test. The HPV
mRNA test alone and HPV mRNA test in combination with ASC-
H+ had high Chi square values. These data indicate that the HPV
mRNA test is a better triage test for women with LSIL than repeat
cytology. The use of HPV mRNA test can reduce the time from
abnormal smear to diagnosis and treatment for CIN2+. Further
Table 5. Outcome for the 297 women triaged with HPV mRNA when combined with cytology with cut-off ASC-US+.
Combination result Outcome % 95% CI
CIN2+ ,CIN2 1) Total 2)
Positive 69 120 189 Specificity 47.4 49.9, 53.8
Negative 0 108 108 PPV 36.5 56.6, 70.4
Total 69 228 297
1),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 (n = 53) and women referred back to screening because of two normal follow-up smears 12
months apart or one normal LBC and a negative HPV result (n = 175).
2)Chi square = 49.3, p,0.001.
doi:10.1371/journal.pone.0024083.t005
Table 6. Outcome for the 297 women triaged with HPV mRNA when combined with cytology with cut-off ASC-H+.
Combination result Outcome % 95% CI
CIN2+ ,CIN2 1) Total 2) Sensitivity 98.6 95.7, 100.0
Positive 68 37 105 Specificity 83.8 79.0, 88.6
Negative 1 191 192 PPV 64.8 55.6, 73.9
Total 69 228 297 NPV 99.5 98.5, 100.0
1),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 (n = 53) and women referred back to screening because of two normal follow-up smears 12
months apart or one normal LBC and a negative HPV result (n = 175).
2)Chi square = 153.5, p,0.001.
doi:10.1371/journal.pone.0024083.t006
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studies are needed in order to reveal whether HPV mRNA testing
and E6/E7 detection may replace repeat cytology in follow-up of
women with cytological low-grade lesions.
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